微创外科途径SAPIEN 3经导管二尖瓣置换早期结果
本研究回顾了2017至2019年间16例接受直视下微创外科二尖瓣置换联合经导管主动脉瓣(MVR-TAVR)患者的30天和1年结局。估计30天死亡率为12.5%,1年死亡率为36.2%。微创开胸MVR-TAVR对于二尖瓣病变合并广泛二尖瓣环钙化患者是可接受的替代方案。
要点
- 微创开胸MVR-TAVR可用于广泛二尖瓣环钙化患者
- 估计30天死亡率为12.5%,1年死亡率为36.2%
- 术后可能出现轻中度瓣周漏、左室流出道梗阻或二尖瓣狭窄
核心结论
- 微创开胸MVR-TAVR对于二尖瓣病变合并广泛二尖瓣环钙化患者是可接受的替代方案。
研究设计与样本
- 回顾性研究,纳入2017至2019年间16例接受直视下微创MVR-TAVR的患者。
主要发现
- 16例患者中女性占69%,年龄53至88岁(平均77±9岁)。
- 31%(5/16)为再次手术,13%(3/16)有右心室功能障碍,31%(5/16)有重度肺动脉高压,20%(3/16)有慢性肾病。
- 69%(11/16)行单纯MVR-TAVR,其中58%(7/12)在阻断主动脉下进行,42%(5/12)在心脏颤动下进行;31%(5/16)行同期手术并在阻断主动脉下进行。
- 估计30天死亡率为12.5%,1年死亡率为36.2%。
- 术后即刻1例出现中度瓣周漏,30天随访后另1例出现重度瓣周漏;1例轻度左室流出道梗阻,1例中度二尖瓣狭窄;1年随访时轻度瓣周漏和中度狭窄无变化。
临床怎么用
- 对于二尖瓣病变合并广泛二尖瓣环钙化、传统手术和经导管二尖瓣置换高风险的患者,可考虑微创开胸MVR-TAVR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited surgical options are available for patients with extensive mitral annular calcification. Several reports have shown the feasibility of surgical mitral valve replacement (MVR) using a transcatheter aortic valve in the mitral position (MVR-TAVR). This study reviewed 30-day and 1-year outcomes of a minimally invasive approach for MVR-TAVR. METHODS: Between 2017 and 2019, 16 patients underwent MVR-TAVR under direct vision. Primary end points included overall survival, technical success, and effectiveness. Secondary end points included valve and cardiac hemodynamics postoperatively and during follow up. RESULTS: The 16 patients (69% female) were 53 to 88 years of age (average, 77 ± 9 years). Comorbidities on presentation were as follows: 31% (5 of 16) were reoperative procedures; 13% (3 of 16) of patients had right ventricular dysfunction, 31% (5 of 16) had severe pulmonary hypertension, and 20% (3 of 16) had chronic kidney disease. Isolated MVR-TAVR was performed on 69% (11 of 16) of patients, with a cross-clamp (58%; 7 of 12) or on a fibrillating heart (42%; 5 of 12), whereas concomitant MVR-TAVR was performed in 31% (5 of 16) of patients with a cross-clamp. At follow-up, the estimated 30-day mortality rate was 12.5%, and the 1-year mortality rate was 36.2%. A moderate postoperative paravalvular leak (PVL) was evident immediately in 1 patient, and a severe PVL was noted after 30-day follow-up in another. In addition, 1 patient had mild left ventricular outflow tract obstruction, and another had moderate mitral valve stenosis. At 1-year follow-up, there were no changes in the mild PVL and moderate stenosis identified postoperatively. CONCLUSIONS: Minithoracotomy MVR-TAVR is an acceptable alternative to conventional and transcatheter MVR in patients with mitral valve disease and extensive mitral annular calcification.
引用
- Lamelas J, Alnajar A. Early Outcomes for Surgical Minimally Invasive SAPIEN 3 Transcatheter Mitral Valve Replacement. Ann Thorac Surg. 2020. PMID: 33144106. doi:10.1016/j.athoracsur.2020.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。